Provided by Tiger Trade Technology Pte. Ltd.

KT Corp

23.56
+0.04000.17%
Post-market: 23.560.00000.00%17:46 EST
Volume:1.01M
Turnover:23.78M
Market Cap:11.36B
PE:16.81
High:23.79
Open:23.59
Low:23.46
Close:23.52
52wk High:23.97
52wk Low:16.25
Shares:482.00M
Float Shares:482.00M
Volume Ratio:0.50
T/O Rate:0.21%
Dividend:0.88
Dividend Rate:3.75%
EPS(TTM):1.40
EPS(LYR):0.6458
ROE:5.08%
ROA:2.32%
PB:0.85
PE(LYR):36.48

Loading ...

YKT Corp Sees FY Net Y170.00M

Dow Jones
·
Feb 13

KT Up Nearly 6%, on Track for Highest Close Since May 2008 -- Data Talk

Dow Jones
·
Feb 11

KT Reports Q4 Operating Income, Higher Revenue; Shares Up Pre-Bell

MT Newswires Live
·
Feb 10

KT Skylife Narrows Loss in Q4 2025

MT Newswires Live
·
Feb 09

Kymera Therapeutics: KT-621’s Differentiated Efficacy and Safety Profile Underpins Attractive Risk-Reward in Emerging Oral Atopic Dermatitis Market

TIPRANKS
·
Feb 03

JTEKT Corp 9-Mos Net Y21.35B Vs Net Y9.95B

Dow Jones
·
Feb 03

Kymera Therapeutics initiates dosing in BREADTH Phase 2b trial of KT-621

TIPRANKS
·
Jan 29

KT Corp. on Track for Highest Close Since August 2025 -- Data Talk

Dow Jones
·
Jan 28

Trump Raises Tariffs on South Korean Goods to 25%

Dow Jones
·
Jan 27

KT International Investment Limited Boosts Stake in Kintor Pharma (09939) by 300,000 Shares at HK$2.7 Each

Stock News
·
Jan 22

A Look At Kymera Therapeutics (KYMR) Valuation After KT-621 Trial Update And J.P. Morgan Conference Focus

Simply Wall St.
·
Jan 12

10 Best International Value Stocks to Buy Now

Benzinga_recent_news
·
Jan 10

South Korea Factory Activity Expands On Stronger Exports, PMI Shows

Reuters
·
Jan 02

South Korea Faults KT Femtocell Mismanagement for Security Breach

MT Newswires Live
·
Dec 29, 2025

Did KT-621 Fast Track Status Just Shift Kymera Therapeutics' (KYMR) Investment Narrative?

Simply Wall St.
·
Dec 22, 2025

Kymera Therapeutics (KYMR): Valuation Check After KT-621 Phase 1b Success and FDA Fast Track Nod

Simply Wall St.
·
Dec 21, 2025

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

GlobeNewswire
·
Dec 06, 2025

A Look at Kymera Therapeutics (KYMR) Valuation Following BROADEN2 Phase 2b KT-621 Dosing Milestone

Simply Wall St.
·
Dec 04, 2025

Market Chatter: Police Raid KT Offices Over Alleged Evidence Concealment in Hacking Case

MT Newswires Live
·
Nov 19, 2025

YKT Corp Sees FY Net Y20.00M

Dow Jones
·
Nov 13, 2025